Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026
Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Fineline Cube May 24, 2026
Company Drug

Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi

Fineline Cube Feb 21, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...

Company Drug

Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy

Fineline Cube Feb 21, 2023

Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...

Company Drug

Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023

Fineline Cube Feb 21, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...

Company Deals

Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D

Fineline Cube Feb 21, 2023

China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly...

Company Drug

Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China

Fineline Cube Feb 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment

Fineline Cube Feb 21, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...

Company R&D

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

Fineline Cube Feb 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...

Company Deals

Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development

Fineline Cube Feb 21, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership...

Company Drug

Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study

Fineline Cube Feb 20, 2023

Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...

Policy / Regulatory

CDE Issues Guidelines for Real-World Drug Research and Evidence Framework

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) has released two important documents: the “Guiding Principles of...

Company Policy / Regulatory

China’s 8th Volume-Based Procurement Round Begins Drug Info Filing

Fineline Cube Feb 20, 2023

The national drug alliance procurement office has released a notification initiating the drug information filing...

Company Drug

BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101

Fineline Cube Feb 20, 2023

Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....

Company Drug

Immuno Cure BioTech Launches Phase I HIV/AIDS Vaccine Study

Fineline Cube Feb 20, 2023

China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for...

Company Deals

Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China

Fineline Cube Feb 20, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for...

Company Deals

Hainan Honz Partners with GPI for Pediatric and Maternity Medicine Expansion

Fineline Cube Feb 20, 2023

China-based Hainan Honz Pharmaceutical Co., Ltd (SHE: 300086) has entered into a three-year partnership with...

Company Deals R&D

MoleculeMind Raises Over RMB 100 Million for AI Protein Design Platform

Fineline Cube Feb 20, 2023

MoleculeMind, an artificial intelligence (AI)-empowered protein design platform based in Beijing, has reportedly raised over...

Drug Policy / Regulatory

Zhejiang Suspends Generic Nesina Trading Due to IP Disputes

Fineline Cube Feb 20, 2023

Zhejiang’s Provincial Center for Drug & Medical Device Procurement has issued a notification suspending the...

Policy / Regulatory

China’s 2022 Western Medicine Trade Analysis: Growth and Challenges

Fineline Cube Feb 20, 2023

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...

Company Drug

CDE Awards Priority Review to Eisai’s Lecanemab for Early Alzheimer’s Disease

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) website indicates that Japan-based Eisai’s (TYO: 4523) lecanemab has...

Posts pagination

1 … 565 566 567 … 670

Recent updates

  • Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma
  • Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer
  • Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors
  • Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026
  • Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Company Drug

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.